



Curriculum Vitae

**John Tyler Baber, M.D.**

Research Affiliation

Preferred Research Partners, Inc.

11219 Financial Center Parkway,

Suite 320

Little Rock, AR 72211

(501) 553-9987 Phone

(501) 553-9986 Fax

A handwritten signature in black ink, appearing to read "John Tyler Baber", is written over a horizontal line.

Signature

A handwritten date "8/17/17" in black ink is written over a horizontal line.

Date

**John Tyler Baber, M.D.**

[drbaberp@prp@gmail.com](mailto:drbaberp@prp@gmail.com)

**Education:** University of Arkansas  
Fayetteville, Arkansas

University of Arkansas School of Medicine  
Little Rock, Arkansas, 1975  
Doctor of Medicine

**Internship:** Los Angeles County – University of Southern  
California Medical Center  
Los Angeles, California, 1975-1976

**Fellowship:** Rancho Los Amigos Hospital  
Downsby, California  
DIABETES, 1976-1977

**Residency:** LAC-USC Medical Center  
Los Angeles, California  
INTERNAL MEDICINE, 1977 – 1979

**Fellowship:** Baylor College of Medicine  
Houston, Texas  
GASTROENTEROLOGY, 1979 – 1980

**Fellowship:** University of Texas – Health Science Center  
Dallas, Texas  
HEPATOLOGY, 1980 – 1981

**Work Experience:** Solo Practice  
Gastroenterology/Hepatology  
1981 to Present

Preferred Research Partners, Inc.  
Principal Investigator  
2009 to Present

**Certification/Licensure:** American Board of Internal Medicine  
Gastroenterology  
American Board of Internal Medicine  
Arkansas State Medical Board  
California State Medical Board  
Texas State Medical Board

**Professional Organizations:**

Arkansas Medical Society  
American Gastroenterology Association  
American College of Gastroenterology  
American College of Physicians  
Arkansas Foundation for Medical Care  
President, Arkansas Gut Club, 2001, 2002, 2003  
Medicare Carrier Advisory Committee  
Arkansas-Oklahoma Endoscopic Society  
Chief of Gastroenterology – Baptist Medical Center,  
2003 – 2006

**Research:**

Standard Therapeutic Assessment of Rebetrone Trial  
2000 – 2001

Tegaserod in GI disorders – Novartis  
Protocol CHTF919E2302, 2001 – 2002

Tegaserod (HTP919) – Novartis  
Protocol CHTF919A2306, 2003

Diarrhea-Predominant Irritable Bowel Syndrome  
(27018966IBS2001) – Furiex Pharmaceuticals, 2010-2011

Opioid Induced Constipation (D3820C00005) -  
AstraZeneca, 2010-2012

Chronic Idiopathic Constipation (LUBI-SGCP-05SB07-  
CE), Apotex, Inc., 2011-2011

Opioid Induced Constipation (D3820C00008) – roll-over,  
AstraZeneca, 2011-2012

Chronic Idiopathic Constipation (71060001) – Anchen,  
Novum PRS, 2011-2012

Chronic Idiopathic Constipation (SP304-20210) – Synergy  
Pharmaceuticals, 2011-2013

Opioid Induced Constipation (1107V9221) – Shionogi,  
Inc., 2012-2012

Healthy Adult Phase I (SP1031) – UCB, 2012-2012

Diarrhea-Predominant Irritable Bowel Syndrome (27018966IBS3001) – Furiex Pharmaceuticals, 2012

Diarrhea-Predominant Irritable Bowel Syndrome (LX1033.201-1) – Lexicon Pharmaceuticals, 2012

Diarrhea-Predominant Irritable Bowel Syndrome (ASMP3001) – Tioga Pharmaceuticals, 2012-2013

Crohn's Disease (TU100P2T2) – Tsumura, 2012

Crohn's Disease (CNDO201-003) – Coronado Biosciences, 2012

Gastroesophageal Reflux Disease (SPD557-206) – Shire, 2012

Chronic Idiopathic Constipation (DRGL-USG01-L/2012) – Dr. Reddy's Laboratories, 2012

Chronic Back Pain & Opioid Induced Constipation (ONU3705) – Purdue Pharma, 2013

Opioid Induced Constipation (5945-SOIC-12-05) – Cubist Pharmaceuticals, 2013

Chronic Idiopathic Constipation (00080) – Ferring Pharmaceuticals, 2013

Opioid Induced Constipation (5945-OIC-12-04) – Cubist Pharmaceuticals, 2013

Chronic Idiopathic Constipation (00081) – Ferring Pharmaceuticals, 2013

Diarrhea-Predominant Irritable Bowel Syndrome (NAK-07) – Menarini Pharmaceuticals, 2013

Chronic Idiopathic Constipation (CIC) – Synergy Pharmaceuticals, Inc. – SP304203-01 (CIC-OLE), 2013

Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy – Shionogi, Inc. – 1315V9232, 2013

Chronic Idiopathic Constipation – Synergy  
Pharmaceuticals, Inc. – SP304203-00 (CIC3), 2013

Diabetic Gastroparesis – Evoke Pharma – METO-IN-003,  
2014

Diabetic Gastroparesis – Evoke Pharma – METO-IN-004,  
2014

Incidence of Major Adverse Cardiovascular Events and  
Conversion to Type 2 Diabetes Mellitus in Obese and  
Overweight Subjects with Cardiovascular Disease or  
Multiple Cardiovascular Risk – Eisai Inc. – APD356-G000-  
401 (CAMELLIA), 2014

Active Moderate Crohn’s Disease – Salix Pharmaceuticals,  
Inc. – RECD3125, 2014

Gastric Emptying Time in Diabetic Subjects with  
Gastroparesis – Targacept – TC-6499-12-CLP-005, 2014

Diabetic Gastroparesis – Rhythm Pharmaceuticals – RM-  
131-009, 2015

Diabetic or Idiopathic Gastroparesis – Theravance– 0099,  
2015

Irritable Bowel Syndrome-Constipation – Synergy  
Pharmaceuticals, Inc. – SP304203-04, 2015

Irritable Bowel Syndrome-Constipation &/or Chronic  
Idiopathic Constipation – Forest Research Institute, Inc. –  
LIN-MD-10, 2015

Ulcerative Colitis – Gilead – GS-US-326-1100, 2015

2016: Ferring International Pharmascience Center US,  
Inc., Ulcerative Colitis -000174, 2016

Ferring International Pharmascience Center US, Inc.,  
Ulcerative Colitis -000175, 2016

Conatus Pharmaceuticals, Non-alcoholic Steatohepatitis  
(NASH) - IDN-6556-12, 2016

Synergy Pharmaceuticals, Irritable Bowel Syndrome with Constipation (IBS-C) - 'SP304203-06, 2016

Braintree Laboratories, Chronic Constipation -BLI400-302, 2016

Braintree Laboratories, Opioid Induced Constipation - BLI801-203, 2016

**Personal:**

Name – John Tyler Baber, M.D.  
Birthplace – St. Louis, Missouri  
Birth Date – June 26, 1950  
Email – [drbaberprp@gmail.com](mailto:drbaberprp@gmail.com)

**Business Address:**

Doctor's Building  
500 South University Avenue  
Suite 103  
Little Rock, AR 72205

Preferred Research Partners, Inc.  
11219 Financial Center Parkway  
Suite 320  
Little Rock, AR 72211